AustralianSuper Pty Ltd Invests $1.11 Million in argenex SE $ARGX

AustralianSuper Pty Ltd purchased a new position in shares of argenex SE (NASDAQ:ARGX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,323 shares of the company’s stock, valued at approximately $1,113,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Pinnacle Associates Ltd. acquired a new stake in shares of argenex during the 4th quarter worth approximately $364,000. Allworth Financial LP increased its holdings in shares of argenex by 12.7% during the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after buying an additional 13 shares during the last quarter. Independent Advisor Alliance increased its holdings in shares of argenex by 0.5% during the 4th quarter. Independent Advisor Alliance now owns 8,651 shares of the company’s stock worth $7,275,000 after buying an additional 47 shares during the last quarter. Valeo Financial Advisors LLC increased its holdings in shares of argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after buying an additional 12 shares during the last quarter. Finally, NewEdge Wealth LLC increased its holdings in shares of argenex by 269.0% during the 4th quarter. NewEdge Wealth LLC now owns 1,118 shares of the company’s stock worth $940,000 after buying an additional 815 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Down 2.8%

Shares of ARGX stock opened at $799.32 on Friday. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The stock has a market capitalization of $49.71 billion, a PE ratio of 35.59, a P/E/G ratio of 1.31 and a beta of 0.46. The firm has a 50 day moving average of $760.29 and a two-hundred day moving average of $816.75.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The company had revenue of $1.31 billion during the quarter. Analysts expect that argenex SE will post 25.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ARGX shares. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research report on Monday, March 9th. HC Wainwright increased their price objective on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Guggenheim increased their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Finally, Royal Bank Of Canada lowered their price objective on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and an average price target of $1,017.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.